Pfizer-Valneva's Lyme disease vaccine proves over 70% effective in final trial stages

• The vaccine showed 74.8% efficacy in a second planned analysis after the first analysis missed its primary goal due to fewer-than-anticipated Lyme cases in the trial
• Approximately 476,000 people are diagnosed with Lyme disease annually in the U.S. and 132,000 cases are reported in Europe each year
• Valneva expects Pfizer to launch the vaccine in the second half of 2027 following regulatory approval

Summary: Pfizer-Valneva Lyme Disease Vaccine Trial Results

Key Development: Pfizer (U.S.) and Valneva (France) announced Monday that their experimental Lyme disease vaccine, PF-07307405, demonstrated over 70% efficacy in late-stage trials. The vaccine showed 73.2% efficacy 28 days after the fourth dose and 74.8% in a second planned analysis.

Trial Outcome: While the vaccine missed its primary endpoint in the initial analysis due to fewer-than-expected Lyme disease cases during the trial, the second analysis successfully met efficacy targets, giving Pfizer confidence to proceed with regulatory submissions.

Market Context: This would be the first approved Lyme disease vaccine since GlaxoSmithKline (GSK) discontinued its Lymerix vaccine in 2002 due to insufficient consumer demand, leaving a significant unmet medical need.

Market Size: The Centers for Disease Control and Prevention (CDC) estimates approximately 476,000 people are diagnosed and treated for Lyme disease annually in the U.S., with around 132,000 cases reported yearly in Europe.

Timeline: Pfizer plans to seek U.S. regulatory approval, with Valneva previously indicating an expected launch in the second half of 2027 following approval.

Disease Background: Lyme disease, transmitted through infected blacklegged tick bites, causes fever, headache, fatigue, and characteristic skin rash. Untreated cases can affect joints, heart, and nervous system, though most cases respond to antibiotic treatment.

Market Implications: Success in this indication could provide both companies significant commercial opportunity in a vaccine category with no current competition and substantial patient need across North America and Europe.